Abstract:380 Background: Alternative mRNA splicing is recognized as a key driver of proteomic diversity. In cancer, this splicing process can be altered resulting in generation of aberrant splice variants (SvPs) that can contribute to tumor pathogenesis. However, our understanding of the significance of splice variants in clear cell renal cell carcinoma (ccRCC) is currently limited. Given the lack of actionable genomic mutations in ccRCC, aberrant SpVs may be the avenue to new pathogenic mechanisms and biomarkers. Methods: We implemented a novel pipeline to screen for and select SpVs frequent in and relatively specific to ccRCC. We started with RNA-seq data from the Cancer Cell Line Encyclopedia to identify SpVs specific to ccRCC cell lines. These were then screened across normal tissue in the Genotype-Tissue Expression Project (GTEx) and excluded if expressed. We analyzed bulk RNA-seq data of ccRCC primary tumors obtained from our institutional Total Cancer Care cohort (TCC; n = 111), The Cancer Genome Atlas (TCGA; n = 484) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC; n = 110) to analyze SpV expression in these samples. Using raw proteomics files from the CPTAC portal, proteins were identified and quantified using MaxQuant. Associations of SvP with protein expression were filtered by a Spearman correlation cutoff of +/-0.3. The Enrichr R library was used for pathway enrichment. Finally, we correlated splice variant expression with overall (OS) and cancer-specific survival (CSS). Using LASSO Cox regression analysis, we derived a SpV-based risk score trained on OS from the TCGA cohort and validated on the TCC and CPTAC cohorts. Results: Our pipeline selected 16 previously uncharacterized SpVs, including variants of suspected oncogenes and tumor suppressors. Proteogenomic analysis identified interesting biological associations. Among patients with high levels of EGFR SpV, we found significantly higher expression of the protein regulatory T cell marker CD70 (p adj = 0.03). MVK SvP was highly correlated with 25 proteins enriched for the mTOR pathway (p adj = 0.002). We derived a survival risk score based on expression of 5 SpVs ( PDZD2, COBLL1, PTPN14, RNASET2, FGD1) in the TCGA cohort. This risk score remained significant on multivariate analysis (HR 1.4, p = 0.002) adjusting for covariates including AJCC stage. This was validated on multivariate analysis in the TCC (HR 3.56, p < 0.001) and CPTAC (HR 3.18, p = 0.019) cohorts. Conclusions: Our novel pipeline selected 16 unique SpVs frequent in and relatively specific for ccRCC. Some are associated with proteins expressed in oncogenic pathways, suggesting a potential role in disease pathogenesis. Additionally, our SpV-based risk score is strongly associated with OS and CSS across multiple cohorts. This study provides a template for identifying and characterizing disease-specific aberrant SpVs to aid discovery of new mechanisms and biomarkers.

Colocalised Genetic Associations Reveal Alternative Splicing Variants as Candidate Causal Links for Breast Cancer Risk in 10 Loci

Supplementary Data from Genome-Wide Splicing Quantitative Expression Locus Analysis Identifies Causal Risk Variants for Non–Small Cell Lung Cancer

A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies.

A multi-tissue, splicing-based joint transcriptome-wide association study identifies susceptibility genes for breast cancer

Proteogenomic and Clinical Implications of Unique Recurrent Splice Variants in Clear Cell Renal Cell Carcinoma.

Subcutaneous adipose tissue splice quantitative trait loci reveal differences in isoform usage associated with cardiometabolic traits.

Identification of candidate causal variants and target genes at 41 breast cancer risk loci through differential allelic expression analysis

Integrating Whole Genome and Transcriptome Sequencing to Characterize the Genetic Architecture of Isoform Variation and its Implications for Health and Disease

Genetic control of alternative splicing and its distinct role in colorectal cancer mechanisms

Deciphering Associations Between Three RNA Splicing-Related Genetic Variants and Lung Cancer Risk

Multi-tissue transcriptome-wide association studies identified 235 genes for intrinsic subtypes of breast cancer

Profiles of alternative splicing landscape in breast cancer and their clinical significance: an integrative analysis based on large-sequencing data

The link between aberrant splicing and B cell infiltration in breast cancer hormone therapy

Rare Coding Variants and Breast Cancer Risk: Evaluation of Susceptibility Loci Identified in Genome-Wide Association Studies

Assessing the Impact of Novel BRCA1 Exon 11 Variants on Pre-mRNA Splicing

Overlap between COPD genetic association results and transcriptional quantitative trait loci

Associations Between Genetic Variants in Mrna Splicing-Related Genes and Risk of Lung Cancer: a Pathway-Based Analysis from Published GWASs

Identification of alternative splicing associated with clinical features: from pan-cancers to genitourinary tumors

Subtype-specific alternative splicing events in breast cancer identified by large-scale data analysis

Identification of Alternatively Spliced Mrna Variants Related to Cancers by Genome-Wide ESTs Alignment

Intronic Alterations Inbrca1andbrca2: Effect on Mrna Splicing Fidelity and Expression